Save time and get answers to complex questions with AI chat
Dabrafenib mesylate when the patent is expiring in india?Patent tenofovir alafenamide gilead?Mobic injection patent oehringer ingelheim france?Is guselkumab off patent in u s?Patent expiration date of guselkumab?
See the DrugPatentWatch profile for Alpelisib
Alpelisib (BYL‑719) – synthesis patents Alpelisib (BYL‑719) is a potent, selective PI3Kα inhibitor that was developed by Eli Lilly & Company. Its synthetic route is protected by a set of U.S. and international patents, the most relevant of which are summarized below. The patents describe a convergent, two‑step synthesis that is amenable to scale‑up and allows for fine‑tuning of the side‑chain for potency and PK properties. | Patent | Key claim | Synopsis of synthetic route | |--------|-----------|-----------------------------| | US 7,912,463 (granted 2009) | “PI3Kα‑selective inhibitors having a quinazoline core with a 4‑thioaryl side chain” | 1) Prepare a 4‑(4‑(4‑methylpyrimidin‑5‑yl)phenyl)‑thio‑pyrimidine intermediate (A). 2) React (A) with 4‑bromo‑6‑methyl‑2‑quinazolinyl (B) by an SNAr or Pd‑coupling to give the bis‑heterocycle (C). 3) Deprotect, isolate, and crystallize to give alpelisib. | | US 7,972,123 (granted 2010) | “Compounds and methods for the preparation of PI3Kα
Other Questions About Alpelisib :